Additional license grant fees per under agreement.

No definition available.

Name:	mgnx_AdditionalLicenseGrantFeesUnderAgreement
Namespace Prefix:	mgnx_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Aggregate potential clinical milestone payments available to be earned under collaboration agreement.

+ References

No definition available.

+ Details

Name:	mgnx_AdditionalPotentialClinicalMilestonePaymentsUnderAgreement
Namespace Prefix:	mgnx_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Aggregate potential regulatory and sales milestone payments available to be earned under collaboration agreement.

+ References

No definition available.

+ Details

Name:	mgnx_AdditionalPotentialRegulatoryAndSalesMilestonePaymentsUnderAgreement
Namespace Prefix:	mgnx_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Collaboration and license agreement entered date.

+ References

No definition available.

+ Details

Name:	mgnx_CollaborationAndLicenseAgreementEnteredDate
Namespace Prefix:	mgnx_
Data Type:	us-types:dateStringItemType
Balance Type:	na
Period Type:	duration

- Details

Name:	mgnx_LicenseAndCollaborationAgreementsLineItems
Namespace Prefix:	mgnx_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Number of molecules to be developed and commercialized as per collaborations.

+ References

No definition available.

+ Details

Name:	mgnx_NumberOfMoleculesToBeDevelopedAndCommercializedAsPerCollaborations
Namespace Prefix:	mgnx_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

Period over which upfront payment is to be recognized.

+ References

No definition available.

+ Details

Name:	mgnx_UpfrontPaymentRecognitionPeriod
Namespace Prefix:	mgnx_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

The carrying amount of consideration received or receivable as of the balance sheet date on potential earnings that were not recognized as revenue in conformity with GAAP, and which are expected to be recognized as such within one year or the normal operating cycle, if longer, including sales, license fees, and royalties, but excluding interest income.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 605

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SAB TOPIC 13.A.4(a).Q1)

-URI http://asc.fasb.org/extlink&oid=27012821&loc=d3e214044-122780

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 8

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6935-107765

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 13

-Section A

+ Details

Name:	us-gaap_DeferredRevenueCurrent
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Revenue earned during the period relating to consideration received from another party for the right to use, but not own, certain of the entity's intangible assets. Licensing arrangements include, but are not limited to, rights to use a patent, copyright, technology, manufacturing process, software or trademark. Licensing fees are generally, but not always, fixed as to amount and not dependent upon the revenue generated by the licensing party. An entity may receive licensing fees for licenses that also generate royalty payments to the entity.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.1(e))

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name:	us-gaap_LicensesRevenue
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

The amount of consideration recognized during the period for the milestone or milestones.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 605

-SubTopic 28

-Section 50

-Paragraph 2

-Subparagraph (e)

-URI http://asc.fasb.org/extlink&oid=19771982&loc=SL6892177-166501

+ Details

Name:	us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Details

Name:	us-gaap_CounterpartyNameAxis=mgnx_GileadMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Collaboration and License Agreements - Additional Information 2 (Detail) (USD $)	1 Months Ended	12 Months Ended
	Jan. 31, 2013 Molecule	Dec. 31, 2014	Dec. 31, 2013
License And Collaboration Agreements [Line Items]
Deferred revenue, Current		$ 14,248,000us-gaap_DeferredRevenueCurrent	$ 20,267,000us-gaap_DeferredRevenueCurrent
Gilead [Member]
License And Collaboration Agreements [Line Items]
Collaboration agreement date		January 2013
Commercialization of molecules	4
License grant fees		7,500,000
Expected period of development		21 months
Recognized revenue under agreement		5,500,000	8,000,000
Milestone achieved		0	0
Deferred revenue, Current		0	3,600,000
Gilead [Member] \| Minimum [Member]
License And Collaboration Agreements [Line Items]
Regulatory and sales milestone		240,000,000
Gilead [Member] \| Maximum [Member]
License And Collaboration Agreements [Line Items]
Regulatory and sales milestone		250,000,000
Gilead [Member] \| Pre-Clinical Milestones [Member] \| Minimum [Member]
License And Collaboration Agreements [Line Items]
Clinical milestone payments		20,000,000
Gilead [Member] \| Pre-Clinical Milestones [Member] \| Maximum [Member]
License And Collaboration Agreements [Line Items]
Clinical milestone payments		$ 25,000,000